Jason Zemansky
Stock Analyst at B of A Securities
(0)
# 3234
Out of 5,287 analysts
37
Total ratings
53.33%
Success rate
1.72%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Insmed | Maintains: Strong Buy | 92 96 | 79.41 | 20.89% | 9 | Mar 20, 2025 | |
Arcus Biosciences | Maintains: Neutral | 22 17 | 9.15 | 85.79% | 5 | Feb 19, 2025 | |
Kura Oncology | Maintains: Buy | 36 29 | 7.66 | 278.59% | 2 | Nov 22, 2024 | |
Syndax Pharmaceutica... | Maintains: Strong Buy | 30 31 | 13.74 | 125.62% | 3 | Aug 15, 2024 | |
Esperion Therapeutic... | Downgrades: Underperform | 3 3 | 1.74 | 43.68% | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 70 60 | 46.59 | 28.78% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underperform | 391 23 | n/a | n/a | 2 | Dec 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 230 | n/a | n/a | 1 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 9 10 | 1.12 | 792.86% | 4 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 450 162 | n/a | n/a | 1 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 145 155 | 0.25 | 61900% | 2 | Dec 13, 2021 |